Treatment of Collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
AssigneeCuRNA, Inc.
InventorsJoseph Collard, Olga Khorkova Sherman
Life of this patent
Estimating the term…
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Collagen gene, in particular, by targeting natural antisense polynucleotides of a Collagen gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Collagen genes.
Claims14
A method of upregulating a function of and/or the expression of a Collagen gene polynucleotide having SEQ ID NO:
- 3 in patient cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one antisense oligonucleotide of 10-30 nucleotides in length that targets, is 100% complementary to and specifically hybridizes to a complementary region of a natural antisense oligonucleotide of the Collagen gene polynucleotide having SEQ ID NOS:
- 6, 7, 8 or 9 thereby upregulating a function of and/or the expression of the Collagen gene polynucleotide in patient cells or tissues in vivo or in vitro.
A method of treating a disease associated with the under expression of at least one Collagen gene polynucleotide and/or at least one encoded product thereof, comprising:
- administering to a patient a therapeutically effective dose of at least one antisense oligonucleotide of 10 to 30 nucleotides in length that is 100 percent complementary to and binds to a natural antisense sequence of said at least one Collagen gene polynucleotide having SEQ ID NOS:
- 3 and upregulates expression of said at least one Collagen gene polynucleotide;
- thereby treating the disease associated with the at least one Collagen gene polynucleotide and/or at least one encoded product thereof.
A method of treating a skin condition associated with the under expression of a Collagen gene polynucleotide having SEQ ID NO:
- 3 and/or at least one encoded product thereof, comprising:
- administering to a patient having a skin condition or at risk of developing a skin condition a therapeutically effective dose of at least one antisense oligonucleotide of 10 to 30 nucleotides in length that is 100 percent complementary to and that binds to a natural antisense sequence of said at least one Collagen gene polynucleotide selected from the group consisting of SEQ ID NOS:
- 3 and upregulates expression of said at least one Collagen gene polynucleotide;
- thereby treating the disease skin condition associated with the at least one Collagen gene polynucleotide and/or at least one encoded product thereof.
Dependencies are inferred from the claim text.